Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck

Not Recruiting

Trial ID: NCT00725764


This study is being conducted to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in adult subjects with squamous cell carcinoma of the head and neck (SCCHN). GSK1363089 is a new chemical entity that inhibits multiple receptor tyrosine kinases (RTKs) with growth-promoting and angiogenic properties. The primary targets of GSK1363089 are the HGF and vascular endothelial growth factor (VEGF) RTK families (eg, MET, VEGFR2/kinase insert domain receptor [KDR]). Since MET overexpression has been associated with poorer prognosis and MET tyrosine kinase mutations have been reported in SCCHN, inhibition of MET receptor and VEGFR2/KDR activation by agents such as GSK1363089 may be of therapeutic benefit in this patient population.

Official Title

A Phase 2 Study of the MET RTK Inhibitor GSK1363089 (Formerly XL880) in Subjects With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Stanford Investigator(s)

A. Dimitrios Colevas, MD
A. Dimitrios Colevas, MD

Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)

Harlan Pinto
Harlan Pinto

Associate Professor of Medicine (Oncology) and of Otolaryngology - Head & Neck Surgery


Inclusion Criteria:

   - The subject has a histologically or cytologically confirmed diagnosis of SCCHN and

   - has recurrent and/or metastatic disease

   - is not eligible for curative intent surgery or radiotherapy

   - has no history of uncontrolled tumor bleeding including hemoptysis in patients with
   documented pulmonary metastasis.

   - The subject has measurable disease, defined as at least one lesion that can be
   accurately measured in at least one dimension (longest diameter to be recorded) as =20
   mm with conventional techniques, or as =10 mm with spiral computerized tomography (CT)

   - Subject is capable of swallowing capsules.

   - Fifteen unstained slides of tumor tissue, archival or fresh, or paraffin block are
   available, and there - confirmation that samples have been sent for analysis at the
   central laboratory.

   - The subject is at least 18 years old.

   - The subject has an Eastern Cooperative Oncology Group (ECOG) performance status =1.

   - In the adrenocorticotropic hormone (ACTH) stimulation test, the subject has a serum
   cortisol level =20 µg/dL (552 nmol/L) 30-90 minutes after injection of ACTH.

   - The subject has organ and marrow function as follows: absolute neutrophil count (ANC)
   =1500/mm3, platelets =100,000/mm3, hemoglobin =9 g/dL, bilirubin =1.5 mg/dL, serum
   creatinine =1.5 mg/dL and/or calculated creatinine clearance =60 mL/min, alanine
   aminotransferase (ALT) and aspartate aminotransferase (AST) =2.5 times the upper limit
   of normal if no liver involvement or =5 times the upper limit of normal with liver

   - The subject has signed the informed consent document.

   - Sexually active subjects must use a medically accepted method of contraception during
   the course of the study.

   - Female patients of childbearing potential must have a negative pregnancy test at

   - The subject has had no other diagnosis of malignancy (unless non-melanoma skin cancer,
   in situ carcinoma of the cervix, or a malignancy diagnosed =5 years ago, and has had
   no evidence of disease for 5 years prior to screening for this study).

Exclusion Criteria:

   - The subject has received radiation to >25% of his or her bone marrow within 30 days of
   GSK1363089 treatment.

   - The subject has received an investigational drug within 30 days (or <5.5 half lives)
   of the first dose of study drug.

   - The subject has received more than one regimen of systemic anticancer therapy for
   disease that has recurred or is metastatic. This may include either single-agent or
   combination cytotoxic chemotherapy with radiotherapy or anti-EGFR treatment (eg,
   cetuximab). Adjuvant or neoadjuvant systemic chemotherapy does not count as a regimen
   for recurrent or metastatic disease.

   - The subject has progressed within 6 months after completion of curative intent
   (definitive) treatment for localized/locoregionally advanced disease.

   - The subject has not recovered to National Cancer Institute (NCI) Common Terminology
   Criteria for Adverse Events (CTCAE) v3.0 Grade =1 from adverse events (AEs) due to
   investigational drugs or other medications that were administered more than 30 days
   before study enrollment with the sole exception of persistent Grade 2 peripheral
   neuropathy in patients who have previously received platinum-based therapy.

   - The subject has known brain metastases.

   - The subject has uncontrolled intercurrent illness including, but not limited to,
   ongoing or active infection, symptomatic congestive heart failure, unstable angina
   pectoris, cardiac arrhythmia, active alcoholism, or psychiatric illness that would
   limit compliance with study requirements.

   - The subject is pregnant or breastfeeding.

   - The subject is known to be positive for the human immunodeficiency virus (HIV).

   - The subject has an allergy or hypersensitivity to components of the GSK1363089


drug: GSK1363089 (foretinib)

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Ruth Lira

New Trial Alerts

Receive email alerts when trials open to patients.